ReviewWorld journal of gastroenterology2025
Very-early-stage gastric amphicrine carcinoma with mixed histology: A case report and review of literature.
Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmphicrine carcinoma is an extremely rare entity. In this article, we report the first known case of very-early-stage amphicrine carcinoma characterized by a mixed growth pattern with multiple pathological components. CASE SUMMARY: A 59-year-old male patient underwent gastroscopy for abdominal discomfort, which revealed a 1.5 cm elevated lesion on the lower part of the anterior aspect of the gastric body close to the gastric angle. Initial biopsy indicated signet-ring cell carcinoma (SRCC) confined to the mucosa. Following endoscopic submucosal dissection, pathological examination revealed signet-ring cells arranged in both nested clusters and diffuse infiltration demonstrating immunohistochemical positivity for periodic acid-Schiff staining for mucin, chromogranin A, and synaptophysin. The coexistence of these endocrine and exocrine markers supported the diagnosis of amphicrine carcinoma. A mixed growth pattern comprising poorly differentiated adenocarcinoma, neuroendocrine tumor, and SRCC was identified. Whether the amphicrine carcinoma arose directly from multipotent stem cells or differentiation from signet-ring cells remains unclear.
conclusionRoutine neuroendocrine immunohistochemical marker staining for SRCC may improve the diagnosis of amphicrine carcinoma and provide guidance for subsequent treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.